AJOVY demonstrated efficacy and a consistent safety profile in the SPACE trial, making it the first and only calcitonin gene-related peptide (CGRP) antagonist treatment option for both pediatric and ...
PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced today that the U.S. Food and ...
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announces new data from the 4th interim analysis of the PEARL migraine prevention study with AJOVY ® ...
If approved for an expanded pediatric indication, AJOVY would be the first calcitonin gene-related peptide (CGRP) antagonist for migraine prevention in adults and episodic migraine prevention in ...
Please provide your email address to receive an email when new articles are posted on . Ajovy offers “significant efficacy” compared with placebo to address episodic migraine in children and ...
Teva Pharmaceutical Industries’ TEVA late-stage study evaluating Ajovy (fremanezumab) for the prevention of episodic migraine in pediatric and adolescent patients met its primary efficacy endpoint.
PARSIPPANY, N.J. and TEL AVIV, Israel, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results